MINNEAPOLIS (MedPage Today) -- Switching to denosumab (Prolia) from alendronate (Fosamax) in women with low bone mineral density was more effective than switching to risedronate (Actonel), a researcher said here. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment